NCT07202039 Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine
| NCT ID | NCT07202039 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Prisma Health-Upstate |
| Condition | Tobacco-flavored EC |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-04-29 |
| Primary Completion | 2029-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2026-04-29 with a primary completion date of 2029-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project aims to investigate the impact of e-cigarette flavors and usage patterns on achieving harm-reduction milestones in a sample of cigarette smokers with opioid use disorder who are taking buprenorphine
Eligibility Criteria
Inclusion Criteria * Age ≥21 years * Smoke ≥5 CPD for ≥1 year * Daily CC smoker * Willing to switch to EC * Exhaled CO ≥6 ppm * Diagnosed with OUD * Stable on bupropion treatment * In good physical and mental health * Able to use a smartphone * Willing to participate in all study components * Able to provide informed consent Exclusion Criteria * Interested in quitting CC (contemplation stage of change) * Use of EC on ≥4 of the past 30 days * Use of other tobacco products (e.g., cigars, smokeless tobacco) on ≥9 days of the past 30 days * Use of nicotine replacement therapy, smoking cessation medication, or a cessation attempt in the past 30 days * Hypertension * Medical condition that would contraindicate participation * Meet DSM-V criteria for major depressive episode, psychotic episode, or manic episode * Current suicidal ideation or suicide attempt in the past year * Psychiatric hospitalization in the past year * Contemplating pregnancy, currently pregnant, or breastfeeding * Unable to speak and/or read English
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07202039 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Tobacco-flavored EC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07202039 currently recruiting?
Yes, NCT07202039 is actively recruiting participants. Contact the research team at iperico@clemson.edu for enrollment information.
Where is the NCT07202039 trial being conducted?
This trial is being conducted at Greenville, United States.
Who is sponsoring the NCT07202039 clinical trial?
NCT07202039 is sponsored by Prisma Health-Upstate. The trial plans to enroll 90 participants.